View Financial HealthVeradigm 配当と自社株買い配当金 基準チェック /06Veradigm配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新Veradigm Inc. (NasdaqGS:MDRX) announces an Equity Buyback for $250 million worth of its shares.Jan 12+ 1 more updateすべての更新を表示Recent updatesVeradigm Appoints Divesh Singla as Managing Director, India OperationsApr 29Veradigm Inc. Announces Chief Financial Officer ChangesApr 07Veradigm Inc. announced delayed annual 10-K filingMar 18Veradigm Inc. Receives Letter from the Division of Enforcement of the U.S. Securities and Exchange CommissionFeb 26Veradigm Inc. Provides Preliminary Unaudited Revenue Guidance for Fiscal Year Ended December 31, 2025Feb 18Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey SolutionFeb 13Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent PracticesJan 29Veradigm and Meperia Launch Industry-First 8-Way Match EDI Platform to Strengthen Healthcare Supply Chain IntegrityJan 16Veradigm Announces Enhancements to the Artificial Intelligence (Ai) Enhanced Ambient Scribe SolutionNov 18Veradigm Inc. announced delayed 10-Q filingNov 13Veradigm Appoints Tehsin Syed as Chief Product and Technology OfficerNov 05Veradigm Inc. Reaffirms the Earnings Guidance for Fiscal Year 2025Oct 01Veradigm Inc. Announces Appointment of Don Trigg as Chief Executive Officer , Effective as of September 2, 2025Aug 19+ 1 more updateVeradigm Inc. announced delayed 10-Q filingAug 08Veradigm Inc. Provides Earnings Guidance for the First Quarter and Reaffirms Earnings Guidance for the Full Year 2025Jun 24Veradigm Inc. announced delayed 10-Q filingMay 13Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data CurationMay 12Veradigm Inc. Updates Earnings Guidance for the Fiscal 2023Mar 19+ 3 more updatesVeradigm Inc. to Report Fiscal Year 2024 Results on Mar 18, 2025Mar 14Veradigm Inc. announced delayed annual 10-K filingMar 05Veradigm Inc. Appoints Two New Independent Directors, Vinit Asar and Louis SilvermaFeb 23Veradigm Inc. Introduces Cardiometabolic Clinical Registry Datasets to Enhance the Next Generation of Real-World ResearchFeb 18Veradigm Announces Board ChangesJan 31Veradigm Launches an Ambient Scribe Advancement to Ease the Healthcare Administrative BurdenNov 21Veradigm Inc. announced delayed 10-Q filingNov 14McKesson, Oracle, Thoma Bravo Reportedly Among Finalists to Acquire VeradigmNov 12Veradigm Inc. announced delayed 10-Q filingAug 13Holmusk and Veradigm Reach New Data Enrichment Milestone in Strategic CollaborationJul 25Veradigm Inc. Is Reaffirms Earnings Guidance for Fiscal 2024May 30Veradigm Inc. Announces Interim Chief Executive Officer ChangesMay 29Veradigm Inc. announced delayed 10-Q filingMay 15Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Notify the Nasdaq's Determination to Delist Veradigm's Securities from ListingApr 27Veradigm Inc. Provides Earnings Guidance for the Fiscal Year 2024Mar 13Veradigm Inc. (OTCPK:MDRX) completed the acquisition of Cascade Bio, IncMar 05Veradigm Inc. announced delayed annual 10-K filingMar 03Veradigm Inc.(OTCPK:MDRX) dropped from NASDAQ Composite IndexMar 01Veradigm Receives Expected Delisting Notice from NasdaqFeb 29Investor sentiment deteriorates as stock falls 18% Feb 28Veradigm Inc. signed a definitive agreement to acquire Cascade Bio, Inc.Feb 28Veradigm (NASDAQ:MDRX) Is Doing The Right Things To Multiply Its Share PriceFeb 28Price target decreased by 12% to US$14.33 Feb 13Veradigm Inc. Revises Earnings Guidance for the Fiscal 2023Jan 10Robbins Geller Rudman & Dowd LLP Files Amended Class Action Lawsuit Against Veradigm IncJan 06Nasdaq Hearings Panel Grants Veradigm's Request for Continued Listing on the Nasdaq Capital Market, Subject to Demonstrating Compliance with Nasdaq Listing Rule 5250(C)(1) on or Before February 27, 2024Dec 14Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Veradigm IncDec 12Veradigm Inc. to Enhance Independent Practice Financial Management with AI for Practice Fusion Billing ServicesDec 11Veradigm Inc. Announces CEO ChangesDec 10Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Veradigm IncNov 26Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-QNov 18Veradigm Inc. announced delayed 10-Q filingNov 14Veradigm (NASDAQ:MDRX) Might Have The Makings Of A Multi-BaggerNov 10Veradigm to Simplify Patient Payment Journey with Veradigm Intelligent PaymentsNov 08Veradigm Inc. Announces Receipt of Nasdaq Stay ExtensionOct 10Veradigm Inc. Announces Receipt of Nasdaq Delisting Notice and Intent to AppealSep 23Veradigm Inc. Provides Revenue Guidance for the Fiscal Year 2023Sep 19Veradigm Inc. announced delayed 10-Q filingAug 11Veradigm Receives Approval from Nasdaq Regarding its Plan to Regain Compliance with Nasdaq Listing Rule 5250(c)(1)Jun 14Veradigm Receives Nasdaq Notice Regarding Delayed Form 10-Q FilingMay 22Veradigm Inc. announced delayed 10-Q filingMay 12Price target decreased by 7.1% to US$19.19 Apr 12Price target decreased by 9.1% to US$20.07 Apr 01Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading HigherMar 06Investor sentiment deteriorates as stock falls 15% Mar 02CEO & Director notifies of intention to sell stock Feb 24CEO & Director notifies of intention to sell stock Feb 21Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?Feb 13Consensus EPS estimates fall by 11% Jan 30Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value EstimateJan 22Veradigm Inc. (NasdaqGS:MDRX) announces an Equity Buyback for $250 million worth of its shares.Jan 12+ 1 more updateLeanTaaS Inc. acquired Hospital IQ, Inc.Jan 11These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably WellJan 04Insider notifies of intention to sell stock Dec 21Independent Director recently sold US$797k worth of stock Dec 10Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)Dec 03CEO & Director notifies of intention to sell stock Nov 25CEO & Director notifies of intention to sell stock Nov 23CEO & Director notifies of intention to sell stock Nov 20Insider notifies of intention to sell stock Nov 18Third quarter 2022 earnings: EPS misses analyst expectations Nov 04Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2% Sep 28Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?Sep 17Chief Financial Officer recently sold US$116k worth of stock Sep 16Chief Financial Officer notifies of intention to sell stock Aug 27Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To PersistAug 24Chief Financial Officer notifies of intention to sell stock Aug 23Chief Financial Officer recently sold US$70k worth of stock Aug 20Consensus forecasts updated Aug 15Second quarter 2022 earnings released: EPS: US$0.028 (vs US$0.16 in 2Q 2021) Aug 05We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its DebtJul 31決済の安定と成長配当データの取得安定した配当: MDRXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: MDRXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Veradigm 配当利回り対市場MDRX 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (MDRX)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Healthcare Services)1.3%アナリスト予想 (MDRX) (最長3年)0%注目すべき配当: MDRXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: MDRXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: MDRXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: MDRXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 03:15終値2026/05/01 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Veradigm Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。29 アナリスト機関Jasper HellwegArgus Research CompanyMatthew GillmorBairdLawrence MarshBarclays26 その他のアナリストを表示
Veradigm Inc. (NasdaqGS:MDRX) announces an Equity Buyback for $250 million worth of its shares.Jan 12+ 1 more update
Veradigm Inc. Receives Letter from the Division of Enforcement of the U.S. Securities and Exchange CommissionFeb 26
Veradigm Inc. Provides Preliminary Unaudited Revenue Guidance for Fiscal Year Ended December 31, 2025Feb 18
Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent PracticesJan 29
Veradigm and Meperia Launch Industry-First 8-Way Match EDI Platform to Strengthen Healthcare Supply Chain IntegrityJan 16
Veradigm Announces Enhancements to the Artificial Intelligence (Ai) Enhanced Ambient Scribe SolutionNov 18
Veradigm Inc. Announces Appointment of Don Trigg as Chief Executive Officer , Effective as of September 2, 2025Aug 19+ 1 more update
Veradigm Inc. Provides Earnings Guidance for the First Quarter and Reaffirms Earnings Guidance for the Full Year 2025Jun 24
Veradigm Inc. Introduces Cardiometabolic Clinical Registry Datasets to Enhance the Next Generation of Real-World ResearchFeb 18
Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Notify the Nasdaq's Determination to Delist Veradigm's Securities from ListingApr 27
Nasdaq Hearings Panel Grants Veradigm's Request for Continued Listing on the Nasdaq Capital Market, Subject to Demonstrating Compliance with Nasdaq Listing Rule 5250(C)(1) on or Before February 27, 2024Dec 14
Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Veradigm IncDec 12
Veradigm Inc. to Enhance Independent Practice Financial Management with AI for Practice Fusion Billing ServicesDec 11
Veradigm Receives Approval from Nasdaq Regarding its Plan to Regain Compliance with Nasdaq Listing Rule 5250(c)(1)Jun 14
Veradigm Inc. (NasdaqGS:MDRX) announces an Equity Buyback for $250 million worth of its shares.Jan 12+ 1 more update
